mCRC Resources
Here you will find relevant materials related to Stivarga® (regorafenib) in mCRC, as well as links to relevant articles and publications.
Stivarga as a targeted alternative after cytotoxic chemotherapy in mCRC
Proven efficacy in mCRC across clinical trials and real-world evidence
PP-STI-GB-0199 | February 2024